Xbrane Biopharma AB

XBRANE

SE0007789409

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 03:20:21 2024-05-21 am EDT			5-day change	1st Jan Change
0.229 ^SEK	0.00%		+6.51%	-97.71%

May. 16	Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024
May. 16	Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Xbrane Biopharma AB Elects Mats Thorén as Director

May 14, 2020 at 12:30 pm EDT

Xbrane Biopharma AB (publ) announced at the AGM held on May 14, 2020, the shareholders elected Mats Thorén as director.

Latest news about Xbrane Biopharma AB

Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024	May. 16
Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 16	CI
Transcript : Xbrane Biopharma AB - Special Call	May. 13
Xbrane Biopharma, Stada Sign US Licensing Deal for Lucentis Biosimilar	May. 10	MT
Xbrane Biopharma AB Appoints Kristoffer Bissessar Was Elected as New Director	May. 02	CI
Transcript : Xbrane Biopharma AB - Special Call	Apr. 22
Xbrane Biopharma AB(OM:XBRANE) dropped from S&P Global BMI Index	Mar. 17	CI
Transcript : Xbrane Biopharma AB, 2023 Earnings Call, Feb 26, 2024	Feb. 26
Xbrane Biopharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI
Xbrane Biopharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Xbrane Biopharma AB(OM:XBRANE) added to OMX Nordic Small Cap Index	Jan. 04	CI
Xbrane Biopharma AB Announces Appointment of Nomination Committee	Dec. 20	CI
Transcript : Xbrane Biopharma AB, Nine Months 2023 Earnings Call, Nov 30, 2023	Nov. 30
Xbrane Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 30	CI
Xbrane Biopharma AB Focuses on Development Portfolio and Introduces A Cost-Savings Scheme	Nov. 23	CI
Xbrane Biopharma AB Presents Nomination Committee	23-10-18	CI
Transcript : Xbrane Biopharma AB, H1 2023 Earnings Call, Aug 29, 2023	23-08-29
Xbrane Biopharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
Certain Shares of Xbrane Biopharma AB are subject to a Lock-Up Agreement Ending on 21-AUG-2023.	23-08-20	CI
Certain Shares of Xbrane Biopharma AB are subject to a Lock-Up Agreement Ending on 21-AUG-2023.	23-08-20	CI
Transcript : Xbrane Biopharma AB - Shareholder/Analyst Call	23-07-25
US FDA Accepts Xbrane Biopharma’s Filing for Eye Disease Inhibitor	23-06-21	MT
Xbrane Biopharma AB Announces U.S. FDA Filing Acceptance for A LucentisÂ®? (Rranibizumab) Biosimilar Candidate	23-06-21	CI
Transcript : Xbrane Biopharma AB, Q1 2023 Earnings Call, May 31, 2023	23-05-31
Xbrane Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI

Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.

Sector

Biotechnology & Medical Research

Calendar

2024-07-17 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Xbrane Biopharma AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.229 SEK

Average target price

0.625 SEK

Spread / Average Target

+172.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
XBRANE BIOPHARMA AB	-97.71%	32.75M
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+49.22%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B

Other Biotechnology & Medical Research